衆生藥業(002317.SZ):衆生睿創一類創新藥RAY1225注射液II期臨牀試驗獲得頂線分析數據結果
格隆匯5月6日丨衆生藥業(002317.SZ)公佈,公司控股子公司廣東衆生睿創生物科技有限公司(簡稱“衆生睿創”)自主研發的一類創新多肽藥物RAY1225注射液,於近日獲得減重和降糖兩項II期臨牀試驗劑量擴展組的頂線分析數據。初步結果表明,RAY1225注射液3~9mg在中國成人肥胖/超重參與者和2型糖尿病參與者中表現出積極的療效和良好的安全性,試驗結果理想,達到預期目的。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.